AbbVie: Neoplasms trials

The registry lists 95 Neoplasms studies with AbbVie as lead sponsor. 19 are open to participants now and 5 have results posted.

Phase 1 55Phase 2 22Phase 3 12No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab InjectionsNot yet recruitingNCT07862764
• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07821684Phase 3
• A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersRecruitingNCT07769502Phase 2
• A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT07744126Phase 2
• A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07728188Phase 3
• A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)RecruitingNCT07409246Phase 1
• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerRecruitingNCT07365241Phase 3
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07155187Phase 2/3
• A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesRecruitingNCT07024784Phase 2
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseaseRecruitingNCT07023289Phase 2
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07005102Phase 2/3
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingNCT06953960Phase 1/2
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
• A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT05650632Phase 1
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaRecruitingNCT05587049
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Phase 3
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04895436Phase 2
• A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological MalignanciesRecruitingNCT03557619Phase 1
• Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingRecruitingNCT03342144
• A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT05513703Phase 2Results posted
• Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedNCT05041257Phase 2Results posted
• First-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsCompletedNCT04622774Phase 1/2Results posted
• Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisCompletedNCT04472598Phase 3Results posted
• A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)TerminatedNCT04161885Phase 3Results posted
• Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)Active, not recruitingNCT07387471Phase 2
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive, not recruitingNCT06667687Phase 1
• Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Active, not recruitingNCT06632951Phase 2
• A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in SpainActive, not recruitingNCT06125795
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabActive, not recruitingNCT06107413Phase 2
• A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in ItalyCompletedNCT06058741
• Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05822752Phase 2
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsActive, not recruitingNCT05618028Phase 1
• Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsActive, not recruitingNCT05599984Phase 1
• A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United KingdomCompletedNCT05555979
• A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT05512390Phase 1
• Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingNCT05456685Phase 2
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in CanadaTerminatedNCT05424562
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in GreeceCompletedNCT05317494
• A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 TabletsActive, not recruitingNCT05308654Phase 1
• A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanActive, not recruitingNCT05286229Phase 1
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05259839Phase 1
• A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax TabletsCompletedNCT05215639
• Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)CompletedNCT04826523
• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsActive, not recruitingNCT04721015Phase 1
• Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
• Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingNCT04454658Phase 1
• First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic TumorsCompletedNCT04417465Phase 1
• An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung CancerTerminatedNCT04189614Phase 1
• A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical PracticeCompletedNCT04178317
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingNCT04041050Phase 1
• A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03893955Phase 1
• An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03821935Phase 1
• A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid TumorsCompletedNCT03595059Phase 1
• Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruitingNCT03539536Phase 2
• Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic LeukemiaCompletedNCT03415035
• A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03314181Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid TumorsCompletedNCT03311477Phase 1
• A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesCompletedNCT03236857Phase 1
• A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)CompletedNCT03234712Phase 1
• A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)TerminatedNCT03145909Phase 1
• A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic MalignanciesCompletedNCT03082209Phase 1
• A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT03071757Phase 1
• A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsCompletedNCT03000257Phase 1
• A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsActive, not recruitingNCT02988960Phase 1
• A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid TumorsCompletedNCT02955251Phase 1
• A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid TumorsCompletedNCT02210663Phase 1
• A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingNCT02099058Phase 1
• A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid TumorsTerminatedNCT01963715Phase 1
• A Study of ABT-165 in Subjects With Solid TumorsCompletedNCT01946074Phase 1
• A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid TumorsCompletedNCT01617928Phase 1
• Study of ABT-700 in Subjects With Advanced Solid TumorsCompletedNCT01472016Phase 1
• An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor TypesCompletedNCT01472003Phase 1
• An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT01413893Phase 1
• An Extension Study of ABT-806 in Subjects With Advanced Solid TumorsCompletedNCT01406119Phase 1
• A Study of ABT-806 in Subjects With Advanced Solid Tumor TypesCompletedNCT01255657Phase 1
• To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid TumorsCompletedNCT01199224Phase 1
• ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid TumorsCompletedNCT01110486Phase 1
• A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsCompletedNCT01063816Phase 1
• Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With CancerCompletedNCT00982566Phase 1
• Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid TumorsCompletedNCT00891605Phase 1
• Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid TumorsCompletedNCT00887757Phase 1
• Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersCompletedNCT00788684Phase 1
• A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid TumorsCompletedNCT00721669Phase 1
• A Phase 1 Study of ABT-869 in Subjects With Solid TumorsCompletedNCT00718380Phase 1
• A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesCompletedNCT00649207Phase 1
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsCompletedNCT00526617Phase 1
• Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer PatientsCompletedNCT00473577Phase 1
• A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2
• Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) CancerCompletedNCT00134186Phase 2
• Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain MetastasesTerminatedNCT00121420Phase 2
• Study of Motexafin Gadolinium and Docetaxel for Advanced CancerCompletedNCT00120939Phase 1
• Study of Motexafin Gadolinium and Docetaxel for Advanced Solid TumorsCompletedNCT00080041Phase 1
• Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)CompletedNCT00054795Phase 3